BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 35288525)

  • 1. S100 and CD34 Expressing Mesenchymal Neoplasm With Rare PLEKHH2::ALK Fusion and Response to ALK Inhibition.
    Coppock JD; Schneider MA; Surrey LF; Karakousis GC; Maki RG; Cooper K
    Am J Surg Pathol; 2022 Sep; 46(9):1309-1313. PubMed ID: 35288525
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD30 expression in an emerging group of mesenchymal spindle cell neoplasms with ALK fusion detected by flow cytometry and immunohistochemistry.
    Iwakoshi A; Kikui H; Nakashima R; Goto Y; Ichikawa D; Sasaki E; Sekimizu M; Hattori H; Maeda N
    Genes Chromosomes Cancer; 2024 Feb; 63(2):e23228. PubMed ID: 38380728
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Case report:
    Sheng SJ; Li JM; Fan QH; Liu Y; Chen SY; Zhao M; Gong QX
    Front Oncol; 2022; 12():1007296. PubMed ID: 36387173
    [No Abstract]   [Full Text] [Related]  

  • 4. ALK fusion gene positive lung cancer and 3 cases treated with an inhibitor for ALK kinase activity.
    Kimura H; Nakajima T; Takeuchi K; Soda M; Mano H; Iizasa T; Matsui Y; Yoshino M; Shingyoji M; Itakura M; Itami M; Ikebe D; Yokoi S; Kageyama H; Ohira M; Nakagawara A
    Lung Cancer; 2012 Jan; 75(1):66-72. PubMed ID: 21757253
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ALK-rearranged Mesenchymal Neoplasms: A Report of 9 cases Further Expanding the Clinicopathologic Spectrum of Emerging Kinase Fusion Positive Group of Tumors.
    Dermawan JK; DiNapoli SE; Mullaney KA; Sukhadia P; Agaram NP; Dickson BC; Antonescu CR
    Genes Chromosomes Cancer; 2023 Feb; 62(2):75-84. PubMed ID: 36125853
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ALK inhibitors in the treatment of advanced NSCLC.
    Gridelli C; Peters S; Sgambato A; Casaluce F; Adjei AA; Ciardiello F
    Cancer Treat Rev; 2014 Mar; 40(2):300-6. PubMed ID: 23931927
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical outcomes in ALK-rearranged lung adenocarcinomas according to ALK fusion variants.
    Cha YJ; Kim HR; Shim HS
    J Transl Med; 2016 Oct; 14(1):296. PubMed ID: 27756333
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PLEKHH2-ALK: A Novel In-frame Fusion With Durable Response to Alectinib: Utilizing RNA Sequencing in Search for Hidden Gene Fusions Susceptible to Targeted Therapy.
    Nagasaka M; Fisher A; Chowdhury T; Ge Y; Sukari A
    Clin Lung Cancer; 2021 Jan; 22(1):e51-e53. PubMed ID: 32893122
    [No Abstract]   [Full Text] [Related]  

  • 9. Prevalence and clinicopathological characteristics of ALK fusion subtypes in lung adenocarcinomas from Chinese populations.
    Zheng D; Wang R; Zhang Y; Pan Y; Cheng X; Cheng C; Zheng S; Li H; Gong R; Li Y; Shen X; Sun Y; Chen H
    J Cancer Res Clin Oncol; 2016 Apr; 142(4):833-43. PubMed ID: 26646246
    [TBL] [Abstract][Full Text] [Related]  

  • 10. RAS signaling in ALK fusion lung cancer.
    Hrustanovic G; Bivona TG
    Small GTPases; 2016; 7(1):32-3. PubMed ID: 26901483
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 'Inflammatory myofibroblastic tumour'-like dedifferentiation of anaplastic lymphoma kinase-rearranged lung adenocarcinoma.
    Mason EF; Fletcher CD; Sholl LM
    Histopathology; 2016 Sep; 69(3):510-5. PubMed ID: 26880345
    [TBL] [Abstract][Full Text] [Related]  

  • 12. RET, ROS1 and ALK fusions in lung cancer.
    Takeuchi K; Soda M; Togashi Y; Suzuki R; Sakata S; Hatano S; Asaka R; Hamanaka W; Ninomiya H; Uehara H; Lim Choi Y; Satoh Y; Okumura S; Nakagawa K; Mano H; Ishikawa Y
    Nat Med; 2012 Feb; 18(3):378-81. PubMed ID: 22327623
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ALK-Rearranged Epithelioid and Spindle Cell Neoplasm of the Sinonasal Tract.
    Zhu P; Wang J
    Int J Surg Pathol; 2024 Feb; ():10668969241226699. PubMed ID: 38303518
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Primary NTRK-rearranged spindle cell  neoplasm of bone harboring an HMBOX1::NTRK3 gene fusion.
    Wang Z; Wang J
    Genes Chromosomes Cancer; 2023 Aug; 62(8):477-482. PubMed ID: 36740981
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ALK-rearranged lung cancer in Chinese: a comprehensive assessment of clinicopathology, IHC, FISH and RT-PCR.
    Li Y; Pan Y; Wang R; Sun Y; Hu H; Shen X; Lu Y; Shen L; Zhu X; Chen H
    PLoS One; 2013; 8(7):e69016. PubMed ID: 23922677
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pediatric Non-Myofibroblastic Primitive Spindle Cell Tumors with
    Rakheja D; Park JY; Fernandes NJ; Watt TC; Laetsch TW; Collins RRJ
    Int J Surg Pathol; 2022 Sep; 30(6):706-715. PubMed ID: 35164578
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PLEKHM2-ALK: A novel fusion in small-cell lung cancer and durable response to ALK inhibitors.
    Li T; Zhang F; Wu Z; Cui L; Zhao X; Wang J; Hu Y
    Lung Cancer; 2020 Jan; 139():146-150. PubMed ID: 31794921
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HIP1-ALK, a novel ALK fusion variant that responds to crizotinib.
    Fang DD; Zhang B; Gu Q; Lira M; Xu Q; Sun H; Qian M; Sheng W; Ozeck M; Wang Z; Zhang C; Chen X; Chen KX; Li J; Chen SH; Christensen J; Mao M; Chan CC
    J Thorac Oncol; 2014 Mar; 9(3):285-94. PubMed ID: 24496003
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [A Case of Advanced Lung Squamous Cell Carcinoma with CLIP1-ALK Fusion Gene].
    Yuan Y; Wang Z; Nie X; Zhang P; Li L
    Zhongguo Fei Ai Za Zhi; 2022 Sep; 25(9):696-700. PubMed ID: 36172736
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oncogenic ALK Fusion in Rare and Aggressive Subtype of Colorectal Adenocarcinoma as a Potential Therapeutic Target.
    Yakirevich E; Resnick MB; Mangray S; Wheeler M; Jackson CL; Lombardo KA; Lee J; Kim KM; Gill AJ; Wang K; Gowen K; Sun J; Miller VA; Stephens PJ; Ali SM; Ross JS; Safran H
    Clin Cancer Res; 2016 Aug; 22(15):3831-40. PubMed ID: 26933125
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.